Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA.

Abstract	Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.
Authors	Kentaro To, Noriko Miyake, Yoji Nagasaki, Nobuyuki Shimono
Journal	The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 64 Issue 6 Pg. 389-94 (Dec 2011) ISSN: 0368-2781 [Print] Japan
PMID	22686009 (Publication Type: Case Reports, Journal Article)
Chemical References	Anti-Bacterial Agents Dibekacin Vancomycin arbekacin
Topics	Adult Anti-Bacterial Agents (administration & dosage, blood) Dibekacin (administration & dosage, analogs & derivatives, blood) Drug Monitoring Drug Therapy, Combination Endocarditis (drug therapy, microbiology) Female Humans Methicillin-Resistant Staphylococcus aureus Staphylococcal Infections Treatment Outcome Vancomycin (administration & dosage, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!